TipRanks
Advertisement
Advertisement

BR:VRTX34 Stock Latest News

Vertex Pharmaceuticals price target lowered to $667 from $672 at BofA
The FlyVertex Pharmaceuticals price target lowered to $667 from $672 at BofA
1d ago
VRTX
Vertex Pharmaceuticals to present data on Alyftrek at NACFC
PremiumThe Fly
Vertex Pharmaceuticals to present data on Alyftrek at NACFC
4d ago
VRTX
Vertex Pharmaceuticals price target raised to $576 from $570 at RBC Capital
PremiumThe Fly
Vertex Pharmaceuticals price target raised to $576 from $570 at RBC Capital
5d ago
VRTX
Quantum BioPharma Ltd. (NASDAQ: QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial
PremiumTipRanks Newswire
Quantum BioPharma Ltd. (NASDAQ: QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial
7d ago
BBIO
KRYS
Vertex Pharmaceuticals price target raised to $615 from $585 at UBS
PremiumThe Fly
Vertex Pharmaceuticals price target raised to $615 from $585 at UBS
14d ago
VRTX
Vertex Pharmaceuticals price target raised to $615 from $585 at UBS
PremiumThe FlyVertex Pharmaceuticals price target raised to $615 from $585 at UBS
15d ago
VRTX
Goldman Sachs Reiterates Buy on Vertex as Inaxaplin Data De-Risk Outlook; $653 Price Target Reaffirmed
Premium
Ratings
Goldman Sachs Reiterates Buy on Vertex as Inaxaplin Data De-Risk Outlook; $653 Price Target Reaffirmed
20d ago
VRTX
Vertex Top Pick Affirmed as Inaxaplin Progress Supports Pipeline Upside; $672 Price Target Reiterated
Premium
Ratings
Vertex Top Pick Affirmed as Inaxaplin Progress Supports Pipeline Upside; $672 Price Target Reiterated
20d ago
VRTX
Truist sees ‘significant positive readthrough’ for Maze from Vertex data
PremiumThe Fly
Truist sees ‘significant positive readthrough’ for Maze from Vertex data
21d ago
MAZE
VRTX
Maze jumps 25% to $27.99 after Vertex kidney disease data
PremiumThe Fly
Maze jumps 25% to $27.99 after Vertex kidney disease data
21d ago
MAZE
VRTX
Vertex Pharmaceuticals announces positive results from Phase 2b inaxaplin study
PremiumThe Fly
Vertex Pharmaceuticals announces positive results from Phase 2b inaxaplin study
21d ago
VRTX
Vertex Pharmaceuticals partners with Lindsey Vonn for JOURNAVX awareness
PremiumThe Fly
Vertex Pharmaceuticals partners with Lindsey Vonn for JOURNAVX awareness
28d ago
VRTX
Vertex Pharmaceuticals reinstated with an Overweight at JPMorgan
PremiumThe FlyVertex Pharmaceuticals reinstated with an Overweight at JPMorgan
1M ago
VRTX
Arcturus Therapeutics price target raised to $41 from $20 at Roth Capital
Premium
The Fly
Arcturus Therapeutics price target raised to $41 from $20 at Roth Capital
1M ago
ARCT
VRTX
Vertex Pharmaceuticals resumed with an Overweight at Morgan Stanley
Premium
The Fly
Vertex Pharmaceuticals resumed with an Overweight at Morgan Stanley
1M ago
VRTX
Vertex Pharmaceuticals completes acquisition of Crinetics Pharmaceuticals
PremiumThe Fly
Vertex Pharmaceuticals completes acquisition of Crinetics Pharmaceuticals
1M ago
CRNX
VRTX
Vertex Pharmaceuticals added to US Conviction List at Goldman Sachs
PremiumThe Fly
Vertex Pharmaceuticals added to US Conviction List at Goldman Sachs
1M ago
VRTX
Argenx price target raised to $1,250 from $1,230 at Morgan Stanley
PremiumThe Fly
Argenx price target raised to $1,250 from $1,230 at Morgan Stanley
1M ago
ARGX
VRTX
Private Markets: $1B for Base Power, $545M for Whatnot
PremiumThe Fly
Private Markets: $1B for Base Power, $545M for Whatnot
2M ago
U
GD
Private Markets: Databricks secures $5B as Kalshi targets $40B valuation
PremiumThe FlyPrivate Markets: Databricks secures $5B as Kalshi targets $40B valuation
2M ago
AI
IBM
Vertex: Competitive Threat Eases, Pipeline Strength Supports Unchanged $600 Price Target and Buy Rating
Premium
Ratings
Vertex: Competitive Threat Eases, Pipeline Strength Supports Unchanged $600 Price Target and Buy Rating
2M ago
VRTX
Vertex Pharmaceuticals added to ‘US 1 List’ at BofA
Premium
The Fly
Vertex Pharmaceuticals added to ‘US 1 List’ at BofA
2M ago
VRTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >